APA (7th ed.) Citation

JS, H., RF, S., D, D., S, K., K, D., M, H., . . . HR, S. (2023). Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease. Journal of hematology & oncology, 16(1), 96. https://doi.org/10.1186/s13045-023-01490-w

Chicago Style (17th ed.) Citation

JS, Heitmann, et al. "Phase I Study Evaluating the Fc-optimized FLT3 Antibody FLYSYN in AML Patients with Measurable Residual Disease." Journal of Hematology & Oncology 16, no. 1 (2023): 96. https://doi.org/10.1186/s13045-023-01490-w.

MLA (9th ed.) Citation

JS, Heitmann, et al. "Phase I Study Evaluating the Fc-optimized FLT3 Antibody FLYSYN in AML Patients with Measurable Residual Disease." Journal of Hematology & Oncology, vol. 16, no. 1, 2023, p. 96, https://doi.org/10.1186/s13045-023-01490-w.